Pathogenic germline mutations in BRCA1, BRCA2, PALB2, RAD51C, and RAD51D, all of which are involved in the HR pathway, are known to confer high or moderate penetrance susceptibility to ovarian and/or triple-negative breast cancer. This evidence concerns the gene BRCA2 and triple-negative breast carcinoma.